Immunogenicity and safety of inactivated SARS‐CoV‐2 vaccines in people living with HIV: A longitudinal cohort study

Abstract To clarify the characteristics in immunogenicity and safety of inactivated SARS‐Cov‐2 vaccines among HIV‐infected individuals, a longitudinal cohort study was performed on HIV‐infected and HIV‐uninfected participants with no history of COVID‐19 infection and COVID‐19 vaccine inoculation. Participants information and adverse events were collected. Blood samples were collected on the same day before vaccination, 21 days after the first shot, 28 days after the second shot, 6 months after the second vaccination and 14 days after the third dose to test anti‐receptor‐binding domain IgG antibody, viral load, CD4+, CD8+ T cell count. Our result showed that although HIV‐infected adults with low nadir CD4+ T cell count ≤ 350 cells/mm 3 generate significantly lower immune response after three shots of vaccine compared with HIV‐negative controls, 100% of all the HIV‐infected and healthy controls were seroconverted after the third shot. Seroconversion ratio and antibody level of 190 days after two shots of vaccination for HIV‐infected with nadir CD4+ T cell count ≤ 350 were significantly lower than that of healthy controls. No significant difference was found in viral load among blood samples collected at each time points. CD4 and CD4/CD8 ratio value were found increased greatly after each shot of inoculation in HIV‐infected individuals with nadir CD4+ T cell count ≤ 350. Multiple logistic regression analysis showed that among HIV‐infected individuals, PLWH with CD4+ T cell count ≤ 350 were less likely experience seroconversion 21 days after the first shot, and less likely maintained antibody immunity 6 months post 2nd dose. Adverse events after each inoculation were not serious and recovered within 1 week. In conclusion, inactivated COVID‐19 vaccine was safe and effective in people living with HIV after three shots of vaccination. HIV‐infected individuals with low nadir CD4+ T cell count ≤ 350 was associated with a nonoptimal antibody response. Further vaccination strategies could be developed for those with low CD4+ T cell counts.